Genentech
2024 Summer Intern - Oncology Bioinformatics / Cancer Immunogenomics (gRED)
This job is now closed
Job Description
- Req#: 202312-128353
Implementing one or more AI/ML approaches in close collaboration with colleagues with and without expertise in AI/ML and bioinformatics
Documenting their efforts and code effectively such that colleagues will be able to replicate their efforts before and after their departure
Effectively communicating their technical and scientific findings in both smaller project meetings and larger group presentation formats
More detailed project objectives will be tailored to the candidate’s strengths, and an ideal outcome for the project would be significant contributions to a robust bioinformatic pipeline of patent or publication quality
Intensive 12-week, full-time (40 hours per week) paid internship
Program start dates are in May/June (Summer)
A stipend, based on location, will be provided to help alleviate costs associated with the internship.
Ownership of challenging and impactful business-critical projects.
Work with some of the most talented people in the biotechnology industry.
Must be pursuing a PhD
Must have attained a PhD
Bioinformatics, Computer Science, Biology, Genetics, Bioengineering or related fields
Possess knowledge in human genetics and epigenetics
Strong background in AI/ML modeling
Proficient in at least one of the following programming languages: Python, R, Julia, C, C++, and/or Java
Familiar with Next Generation Sequencing (NGS) data
Experience with programming in an HPC setting
Excellent communication, collaboration, and interpersonal skills
A passion for cancer biology and immunology
Complements our culture and the standards that guide our daily behavior & decisions: Integrity, Courage, and Passion
2024 Summer Intern - Oncology Bioinformatics / Cancer Immunogenomics (gRED)
Department Summary
At Genentech Research & Early Development (gRED), we have embarked on an exciting journey to unite and strengthen our computational talent and capabilities. This endeavor has led to the formation of a new central organization called gRED Computational Sciences (gCS). Our mission at gCS is to collaborate across the organization to unlock the potential of data, technology, and computational approaches. By doing so, we aim to revolutionize the discovery and development of targets and therapeutics, ultimately leading to innovative treatments for patients worldwide.
Within gCS, our group focuses on advanced computational research for development of cancer immunotherapies, specifically in the field of cancer immunogenomics. We currently have an exciting internship opportunity available for highly motivated and academically equipped students. The internship will involve contributing to our research on identifying new targets for cancer immunotherapy. This role offers hands-on experience in computational pre-clinical research. The ideal intern for this role should have a strong background in AI/ML modeling and a passion for cancer biology and genetics.
This internship position is located in South San Francisco, CA on-site.
Key Responsibilities
Program Highlights
Who You Are (Required)
Required education:
You meet one of the following criteria:
Required majors:
Required skills:
Other Preferred Qualifications
Relocation benefits are not available for this job posting.
The expected salary range for this position based on the primary location for this position in California is $50.00 per hour. Actual pay will be determined based on experience, qualifications, geographic location, and other job-related factors permitted by law. This position also qualifies for paid holiday time off benefits.
#GNE-gCS-2024-Interns
Genentech is an equal opportunity employer, and we embrace the increasingly diverse world around us. Genentech prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status.
About the company
Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009.